RECENT ADVANCES IN THE MANAGEMENT OF CHRONIC HEPATITIS B

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KIM SOO RYANG; YANG JISIN; KUDO MASATOSHI; HINO OKIO

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2011 | Volume:11 | Issue:8 (37) Page(s): 601-611

Download Full-Text

View:

296

Download:

345

Cites:

Information Journal Paper

Title

RECENT ADVANCES IN THE MANAGEMENT OF CHRONIC HEPATITIS B

Author(s)

KIM SOO RYANG | YANG JISIN | KUDO MASATOSHI | HINO OKIO | Issue Writer Certificate

Keywords

HEPATITIS B VIRUS

INTERFERON ALPHA

NUCLEOTIDE ANALOGUES

ENTECAVIR

TENOFOVIR

Abstract

There are seven approved treatments for adults with chronic HEPATITIS B VIRUS infection in the United States and European countries: interferon-a, pegylated interferon-a, lamivudine, adefovir dipivoxil, ENTECAVIR, telbivudine, and TENOFOVIR disoproxil fumarate. At present, two new analogues, ENTECAVIR and TENOFOVIR are recommended as the first line therapy by the guidelines of European Association for the Study of the Liver and American Association Study for the Liver Diseases. On the other hand, regarding interferon therapy, use of pegylated interferon-a is recommended as the first line therapy instead of standard interferon-a by both guidelines. Therefore, the main scientific interests and unmet medical needs for treatment of chronic hepatitis B have been narrowed down to long-term efficacy and safety of the two said analogues-entecavir and TENOFOVIR-and combination therapy of pegylated interferon-a with the two analogues. To put it concretely, further studies are needed to assess (1) the long-term efficacy and safety and resistance to ENTECAVIR and TENOFOVIR; (2) the efficacy of different durations (24 weeks to 2 years) and lower doses of pegylated interferon-a; (3) the role of combination therapy with two analogues to reduce resistance; and (4) the efficacy and safety of the two analogues with decompensated cirrhosis. Herein, we review the recent available data and results.

Cites

No record.

References

No record.

Cite

APA: Copy

KIM, SOO RYANG, YANG, JISIN, KUDO, MASATOSHI, & HINO, OKIO. (2011). RECENT ADVANCES IN THE MANAGEMENT OF CHRONIC HEPATITIS B. HEPATITIS MONTHLY, 11(8 (37)), 601-611. SID. https://sid.ir/paper/306446/en

Vancouver: Copy

KIM SOO RYANG, YANG JISIN, KUDO MASATOSHI, HINO OKIO. RECENT ADVANCES IN THE MANAGEMENT OF CHRONIC HEPATITIS B. HEPATITIS MONTHLY[Internet]. 2011;11(8 (37)):601-611. Available from: https://sid.ir/paper/306446/en

IEEE: Copy

SOO RYANG KIM, JISIN YANG, MASATOSHI KUDO, and OKIO HINO, “RECENT ADVANCES IN THE MANAGEMENT OF CHRONIC HEPATITIS B,” HEPATITIS MONTHLY, vol. 11, no. 8 (37), pp. 601–611, 2011, [Online]. Available: https://sid.ir/paper/306446/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops